NCT05796206
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 6 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Feb 2026 to Nov 21, 2024
- Enrollment target: estimated 120 to confirmed 123
- Study completion date changed from estimate of Jul 2026 to Jul 2, 2026
- Secondary endpoints: details revised at 1 of 13 entries
- Site details revised
Notable Phase: Phase 2/3 to Phase 2v4 Show 7 more changesShow less
- Enrollment target: 200 to 120
- Eligibility criteria expanded, about 51 words
- Primary endpoint revised
- Trial status: Recruiting to Active, Not Recruiting
- Secondary endpoints: 10 to 13
- Site details revised
- Study title expanded, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 2023 to May 26, 2023
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Part A and Part B:Percentage of participants achieving SRI-4 at Week 12
Timeframe: at Week 12
Secondary (13)
Part A and Part B:Proportion of participants achieving SRI-4 at Week 52
Part A and Part B:Proportion of participants achieving SRI-4 at Week 24
Part A and Part B:Proportion of participants achieving SRI-4 at Week76
Part A and Part B:Change From Baseline in 24-hour urine protein in participants with elevated baseline urine protein (24-hour urine protein ≥ 0.5g) at Week 24,52,76
Part A and Part B:Percentage of participants who achieved or maintained a prednisone dose of ≤7.5 mg/day (or equivalent dose) during Weeks 40 to 52
Show 8 moreShow less
Part A and Part B:Change From Baseline in EuroQol- 5 Dimension (EQ-5D) at Week 24, 52, 76
Part A and Part B:Change From Baseline in Serum Immunoglobulin Levels at Week 24 Change from baseline in the serum levels of IgG, IgA, IgM
Part A and Part B:Change From Baseline in biomarkers associated with disease anti-dsDNA ,complement component 3 (C3), and complement component 4 (C4)
Part A and Part B:Percentage of Participants with Adverse Events
Part A: Pharmacokinetic(PK) Parameters: AUC
Part A: Pharmacokinetic(PK) Parameters:Cmax
Part A and Part B: Pharmacodynamics(PD) characteristics:summarizing the changes in the absolute counts and percentages of peripheral blood CD19⁺ B cells, CD3⁺CD4⁺ T cells, CD3⁺CD8⁺ T cells, NK cells, CD19⁺CD27⁺ B cells, and CD19⁺CD27- naïve B cells
Part Aand Part B: Anti-Drug Antibodies (ADA) will be tested and percentage of ADA positive patients will be calculated to evaluate immunogenicity of MIL62
Arms and interventions
MIL62(Part A and B)Experimental
Placebo (Part A and B)Placebo comparator
Drugs: MIL62, placebo
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, China